Shirt a Phobia

Sample Page

Relutrigine (INNTooltip International Nonproprietary Name; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache.[1][2][3] It is taken orally.[1] The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers.[2][3] Relutrigine is under development by Praxis Precision Medicines.[1][2] As of May 2026, it is in preregistration for epilepsy.[1] Conversely, no recent development has been reported for headaches.[1]

See also

References

  1. ^ a b c d e f “Praxis-Precision-Medicines”. AdisInsight. 19 May 2026. Retrieved 6 June 2026.
  2. ^ a b c Müller P, Draguhn A, Egorov AV (October 2024). “Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers”. Pflugers Archiv. 476 (10): 1445–1473. doi:10.1007/s00424-024-02980-7. PMC 11381486. PMID 38967655.
  3. ^ a b Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, et al. (March 2022). “The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers”. Epilepsia. 63 (3): 697–708. doi:10.1111/epi.17149. PMC 9304232. PMID 35037706.